Warning: ob_start() [ref.outcontrol]: output handler 'ob_gzhandler' conflicts with 'zlib output compression' in /home/jadolo/public_html/biopharmarena.com/home/wp-includes/functions.php on line 419
BioPharmArena.com » Blog Archive » FDA Approves Cialis(R) (tadalafil) For Once Daily Use For The Treatment Of Erectile Dysfunction

Search:
Main Menu
Login | RSS |

BioPharmArena.com

News, Topics and Careers in Biopharmaceuticals and Biotechnology

FDA Approves Cialis(R) (tadalafil) For Once Daily Use For The Treatment Of Erectile Dysfunction

January 14th, 2008 by Barry - Admin BioPharmArena

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved Cialis(R) (tadalafil)(1) for once daily use (2.5 mg and 5 mg), an oral medication taken once per day to treat erectile dysfunction (ED). When Cialis for once daily use is taken daily, men can attempt sexual activity at anytime between doses.

Currently available in parts of Europe, this low-dose daily treatment option of Cialis may be most appropriate for men with ED who anticipate more frequent sexual activity (e.g. twice weekly). For other men, Cialis taken as needed - the previously approved dosing regimen - may be most appropriate.

In clinical trials, when taken without restrictions on the timing of sexual activity, Cialis for once daily use improved erectile function over the course of therapy.

“ED can be a chronic condition like diabetes or high blood pressure,” said Ridwan Shabsigh, M.D., Director of the Division of Urology at Maimonides Medical Center in New York. “As a urologist, I know couples like to have choices and will appreciate the availability of Cialis for once daily use.”

Cialis for use as needed transformed the U.S. ED market when it was approved in 2003 as the first and only PDE5 inhibitor clinically proven to provide sustained efficacy for up to 36 hours. Cialis for once daily use provides a new option for men who may be looking for a dosing option that can be taken without regard to timing of sexual activity. In consultation with their physician, patients now have the freedom to choose the dosing regimen that is appropriate for them.

Read more ……

Medicalnewstoday.com

Posted in News, Medical Doctors in Clinical Research, Clinical Research and Clincal Trials |

Leave a Comment

Please note: Comment moderation is enabled and may delay your comment. There is no need to resubmit your comment.